GlassScriptPhysician profile
Deborah A Griffin
NPI 1922174309
$11,363.68
in general payments reported to CMS, 2019-2025
60 companies · $2,054 in 2025
The $2,054 reported for 2025 was more than what 94% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,082 · 2022: $2,603 · 2023: $2,670 · 2024: $1,955 · 2025: $2,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,113 · Education: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,112.66 |
| Education | $566.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,195.21 | 2021-2025 | Erleada, Balversa, Akeega |
| E.R. Squibb & Sons, L.L.C. | $893.57 | 2021-2024 | Opdivo, Reblozyl, Pomalyst |
| Seagen INC. | $728.55 | 2021-2025 | Tukysa, Adcetris, Padcev |
| Genzyme Corporation | $660.34 | 2021-2025 | |
| Genentech USA, INC. | $613.33 | 2021-2025 | Tecentriq Hybreza, Tecentriq |
| Astrazeneca Pharmaceuticals LP | $602.22 | 2021-2025 | Imfinzi, Onglyza, Enhertu |
| Incyte Corporation | $472.52 | 2021-2025 | Monjuvi, Zynyz, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $347.20 | 2023-2025 | Libtayo |
| Sobi, INC | $344.07 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $339.68 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $333.82 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Emd Serono, INC. | $316.26 | 2022-2025 | Bavencio |
| Eisai INC. | $314.60 | 2021-2025 | |
| Gilead Sciences, INC. | $300.98 | 2023-2025 | Trodelvy |
| Pfizer INC. | $288.74 | 2022-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $267.61 | 2023-2025 | Xospata, Padcev, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $265.65 | 2021-2024 | Ninlaro |
| Lilly USA, LLC | $257.82 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Abbvie INC. | $213.86 | 2024-2025 | |
| Amgen INC. | $190.29 | 2022-2025 | Evenity, Nplate, Xgeva |
| Pharmacyclics LLC, An Abbvie Company | $183.50 | 2022-2023 | Imbruvica |
| Celgene Corporation | $162.37 | 2021-2025 | Opdivo, Pomalyst |
| Mirati Therapeutics, INC. | $159.64 | 2023 | Krazati |
| Glaxosmithkline, LLC. | $156.64 | 2023-2024 | Ojjaara, Shingrix, Arexvy |
| Beigene USA, INC. | $146.32 | 2023 | Brukinsa |
| Blueprint Medicines Corporation | $134.82 | 2023 | Ayvakit |
| G1 Therapeutics, INC. | $114.26 | 2023 | Cosela |
| Daiichi Sankyo INC. | $107.24 | 2021-2025 | Enhertu |
| Alexion Pharmaceuticals, INC. | $98.50 | 2021-2025 | Ultomiris |
| Kite Pharma, INC. | $87.10 | 2021-2025 | Yescarta |
| Janssen Scientific Affairs, LLC | $83.16 | 2025 | Erleada, Pipeline, Balversa |
| Acadia Pharmaceuticals INC | $79.01 | 2024 | Nuplazid |
| Inspire Medical Systems, INC. | $71.43 | 2023 | Inspire |
| Tersera Therapeutics LLC | $54.31 | 2024-2025 | Xermelo, Zoladex |
| Taiho Oncology, INC. | $48.44 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $47.52 | 2021-2023 | |
| Lundbeck LLC | $43.27 | 2024-2025 | Vyepti, Rexulti |
| Stemline Therapeutics INC. | $41.11 | 2024-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $40.87 | 2025 | Onivyde |
| Puma Biotechnology, INC. | $40.82 | 2025 | |
| Rigel Pharmaceuticals, INC. | $39.91 | 2023-2024 | Rezlidhia, Tavalisse |
| Novo Nordisk INC | $38.72 | 2022 | |
| Karyopharm Therapeutics INC. | $37.48 | 2023 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.96 | 2024 | Gilotrif, Jardiance |
| Deciphera Pharmaceuticals INC. | $34.08 | 2024-2025 | Qinlock |
| Axsome Therapeutics, INC. | $33.21 | 2025 | Auvelity |
| Myriad Genetic Laboratories, INC. | $29.57 | 2024 | Precisetumor |
| Iovance Biotherapeutics, INC. | $26.59 | 2025 | Amtagvi |
| Adc Therapeutics America, INC. | $25.33 | 2024 | |
| Geron Corporation | $24.68 | 2025 | Rytelo |
| Array Biopharma INC | $24.46 | 2024 | Braftovi, Lorbrena, Xalkori |
| Apellis Pharmaceuticals, INC. | $24.41 | 2023 | Empaveli |
| Legend Biotech USA INC. | $21.45 | 2025 | Carvykti |
| Pharmaessentia USA Corporation | $20.67 | 2025 | Besremi |
| Janssen Pharmaceuticals, INC | $18.56 | 2024 | Xarelto |
| Agios Pharmaceuticals, INC. | $17.67 | 2024 | |
| Pharmacosmos Therapeutics INC. | $17.57 | 2024 | Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $17.24 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.44 | 2025 | |
| Kyowa Kirin, INC. | $14.03 | 2023 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.